Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glutamine hydroxamate is a synthetic derivative of the amino acid L-glutamine, in which a hydroxamic acid functional group replaces the amide at the γ-position. This modification confers metal-chelating properties and allows it to act as an inhibitor or substrate for various enzymes, particularly those involved in amino acid and carbohydrate metabolism. Its primary mechanism of action is inhibition of enzymes such as glucosamine 6-phosphate synthase (glmS), where it competes with natural substrates, thereby modulating enzyme activity. It is widely used as a biochemical tool to study enzyme kinetics and metabolic pathways, especially in research on nitrogen metabolism and hexosamine biosynthesis. Glutamine hydroxamate has not been approved for clinical use but serves as an experimental agent in preclinical studies[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glutamine hydroxamate.